Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma (INITIUM Study)

NCT04382664 is registered in ClinicalTrials.gov with Ultimovacs ASA as lead sponsor.

NCT NCT04382664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04382664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma (INITIUM Study)
Lead sponsor
Ultimovacs ASA
Phase
Phase 2
Overall status
Completed
Start date
May 27, 2020
Completion date
April 10, 2024
Enrollment
156 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma